
Nektar Therapeutics (NKTR) Stock Forecast & Price Target
Nektar Therapeutics (NKTR) Analyst Ratings
Bulls say
Nektar Therapeutics is positioned well in the field of immunotherapy, with several promising treatments in development for autoimmune diseases and cancer. The company has a diverse pipeline, including rezpegaldesleukin, a potential treatment for alopecia areata, which presents a significant whitespace against competitors and has the potential for significant revenue. Additionally, the company has a strong financial position, with a cash balance of $33 million and multiple ongoing studies, indicating a positive outlook for the company's future growth and success.
Bears say
Nektar Therapeutics is facing significant risks to its stock outlook due to concerns about potential clinical and regulatory failures for its key drug candidate, rezpegaldesleukin, which is being developed for the treatment of autoimmune diseases and cancer. Additionally, there are potential commercial challenges and logistical issues that could impact the company's ability to generate sales and distribute its drugs in a timely manner. It will be important for the company to successfully navigate these challenges in order to meet its financial projections and maintain investor confidence.
This aggregate rating is based on analysts' research of Nektar Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Nektar Therapeutics (NKTR) Analyst Forecast & Price Prediction
Start investing in Nektar Therapeutics (NKTR)
Order type
Buy in
Order amount
Est. shares
0 shares